Institute of Pediatrics, Department of Medical and Surgical specialty and Public Heath, Perugia, Italy.
Int J Immunopathol Pharmacol. 2009 Oct-Dec;22(4 Suppl):13-6.
Allergen extracts for sublingual immunotherapy (SLIT) are currently marketed by several manufacturers, with administration schedules and amount of allergen(s) quite variable in the different products, although almost all are standardized biologically or immunologically. The allergen extracts for SLIT are available in two main pharmaceutical forms: solution to be delivered by drop-counters, pre-dosed actuators (mini-pumps) or disposable single-dose vials; tablets with appropriate composition that allows a slow (1-2 minutes) dissolution in the mouth in contact with saliva. In Europe, SLIT is prescribed in general for one or a few allergens, and mixtures are less used, though there is no immunological contraindication to give multiple allergens. SLIT traditionally involves a build-up phase and a maintenance phase with the top dose. The build-up phase has usually the duration of 4 - 6 weeks. The patient must start with the lowest concentration and gradually increase, using the different dosage preparations, until the maintenance dose is reached. Rush and ultra-rush inductions have been introduced, based on the safety profile of SLIT that is very favorable. For these reasons it has been suggested that an updosing phase maybe even not necessary. The no-updosing approach would result in a treatment that is more patient-friendly and convenient to manage. Indeed, the most recent randomized trials were performed with the no-updosing regimen and their results in term of safety were as favorable as the studies performed with the traditional updosing approach. The currently recommended duration of SLIT is comprised between 3 and 4 years depending on the clinical response in single patients.
变应原提取物用于舌下免疫治疗(SLIT)目前由几家制造商销售,不同产品的给药方案和过敏原(s)数量差异很大,尽管几乎所有产品在生物学或免疫学上都是标准化的。SLIT 的变应原提取物有两种主要的药物形式:滴剂计数器、预定量驱动器(微型泵)或一次性单剂量小瓶输送的溶液;具有适当组成的片剂,可在口中与唾液接触时缓慢(1-2 分钟)溶解。在欧洲,SLIT 通常规定用于一种或几种过敏原,混合物的使用较少,尽管给予多种过敏原没有免疫禁忌。SLIT 传统上涉及递增期和维持期,维持期使用最高剂量。递增期通常持续 4-6 周。患者必须从最低浓度开始,逐渐增加,使用不同的剂量制剂,直到达到维持剂量。基于 SLIT 非常有利的安全性概况,已经引入了快速和超快速诱导期。出于这些原因,有人建议甚至不需要递增期。不递增期方法可能会导致更适合患者的治疗,并且更便于管理。事实上,最近的随机试验是使用不递增期方案进行的,其安全性结果与使用传统递增期方法进行的研究一样有利。根据单例患者的临床反应,SLIT 的目前推荐持续时间在 3 到 4 年之间。